- Home
- CBOE vs ROIV Comparison
CBOE vs ROIV Comparison
Compare CBOE & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | ROIV |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 28.7B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CBOE | ROIV |
|---|---|---|
| Price | $362.77 | $41.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 13 |
| Target Price | ★ $355.60 | $49.91 |
| AVG Volume (30 Days) | 1.2M | ★ 7.2M |
| Earning Date | 10-30-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 44.52 | N/A |
| EPS | ★ 11.08 | N/A |
| Revenue | ★ $2,229,100,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | $562.28 |
| Revenue Next Year | $4.63 | $734.15 |
| P/E Ratio | $31.97 | ★ N/A |
| Revenue Growth | ★ 239.31 | N/A |
| 52 Week Low | $227.15 | $19.96 |
| 52 Week High | $371.18 | $42.50 |
Technical Indicators
Market Signals| Indicator | CBOE | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 70.28 | 66.22 |
| Support Level | $273.63 | $33.11 |
| Resistance Level | $371.18 | $42.50 |
| Average True Range (ATR) | 12.86 | 1.52 |
| MACD | 2.00 | 0.53 |
| Stochastic Oscillator | 99.07 | 94.46 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.